Solitary fibrous tumours are rare growths that can appear almost anywhere in the body, most often near the lungs. While many grow slowly and remain harmless, others can become aggressive. Understanding the available treatment options—from established surgical approaches to emerging therapies being tested in clinical trials—is essential for managing this complex condition.

Managing a Rare but Complex Condition

When someone receives a diagnosis of solitary fibrous tumour, the primary goal of treatment is to remove the growth completely and prevent it from returning or spreading to other parts of the body. Because these tumours can occur in so many different locations—from the lining around the lungs to the abdomen, head and neck, or even the brain and spinal cord—treatment plans must be carefully tailored to each individual situation. The approach depends heavily on where the tumour is located, how large it has grown, whether it shows signs of aggressive behaviour, and the overall health of the patient.^[1]

Healthcare professionals now classify solitary fibrous tumours into risk categories rather than simply labelling them as benign or malignant. This classification system considers factors such as the patient’s age, the size of the tumour, and what the cells look like under a microscope. Tumours can be categorised as low, intermediate, or high risk, which helps doctors predict how likely they are to come back after treatment or spread to distant parts of the body. This risk assessment is crucial because it guides decisions about how aggressively to treat the tumour and how closely to monitor the patient afterward.^[1]

Standard treatments approved by medical societies focus primarily on surgical removal, sometimes combined with radiation therapy. However, for tumours that cannot be completely removed by surgery, have already spread, or come back after initial treatment, there are ongoing research efforts exploring new therapeutic approaches. Clinical trials are investigating innovative molecules and treatment strategies that may offer hope for patients with advanced or aggressive forms of this disease.^[2]

Standard Treatment Approaches

Surgical Removal as the Primary Treatment

Surgery remains the cornerstone of treatment for solitary fibrous tumours. The goal of the operation is to remove the entire tumour along with a rim of healthy tissue around it, which doctors call “taking a margin.” This margin of normal tissue helps ensure that no cancer cells are left behind. The surgical approach varies significantly depending on where the tumour is located. For tumours in the chest cavity, surgeons may need to perform complex procedures involving the pleura, which is the protective lining around the lungs. When tumours affect the arms or legs, surgeons typically perform limb-sparing surgery, carefully removing the tumour while preserving the function of the limb.^[4]

In rare and extreme cases where the cancer has spread extensively throughout a limb and cannot be removed while preserving limb function, surgeons may need to consider partial or full amputation. However, this is extremely uncommon due to advances in surgical techniques. For tumours located in sensitive areas such as near the eyes, in the sinuses, or around the brain and spinal cord, surgeons work with extreme precision to remove the growth while protecting vital structures and maintaining normal function.^[2]

The complexity of the surgery increases when tumours grow in challenging locations such as the abdomen or pelvis, where they may press against or involve important organs. In these situations, a multidisciplinary team of surgeons with different specialisations may work together to achieve complete removal while minimising damage to surrounding structures. The success of surgery depends greatly on achieving complete removal—when even small amounts of tumour tissue remain, the risk of recurrence increases significantly.^[3]

Radiation Therapy as Additional Treatment

Radiation therapy uses high-energy rays to destroy cancer cells. This treatment may be given either before or after surgery, depending on the specific circumstances. When used before surgery, radiation can help shrink the tumour, making it easier to remove completely. This approach is particularly valuable when the tumour is located in a difficult spot or has grown very large. After surgery, radiation therapy may be recommended to destroy any microscopic cancer cells that might have been left behind, reducing the risk that the tumour will return.^[4]

The decision to use radiation therapy depends on several factors, including the size and location of the tumour, whether it was completely removed during surgery, and its risk category. For tumours classified as high risk, doctors are more likely to recommend radiation therapy even after seemingly successful surgery. The treatment is typically delivered over several weeks, with patients receiving small doses of radiation each day. This fractionated approach allows normal tissues to recover between treatments while maximising damage to any remaining cancer cells.^[3]

Chemotherapy in Standard Care

Chemotherapy involves using drugs to kill cancer cells throughout the body. For solitary fibrous tumours, chemotherapy has historically shown limited effectiveness compared to its use in other types of cancer. However, it may be considered in specific situations, particularly for tumours that cannot be removed by surgery or have already spread to distant organs. Traditional chemotherapy drugs work by targeting rapidly dividing cells, but because many solitary fibrous tumours grow slowly, they may not respond as well to this approach.^[2]

There is one important exception to this pattern: a specific aggressive subtype called dedifferentiated solitary fibrous tumour. This variant grows more rapidly and behaves more aggressively than typical solitary fibrous tumours. Interestingly, while this subtype tends to resist other treatments, it may actually respond better to chemotherapy. This different behaviour means that doctors must carefully identify the specific type of solitary fibrous tumour before deciding on treatment strategies.^[5]

Most Common Treatment Methods

• Surgery
  • Complete surgical removal of the tumour with a margin of healthy tissue
  • Limb-sparing surgery when tumours affect arms or legs to preserve function
  • Complex procedures for tumours in the chest cavity involving the pleura
  • Precision surgery for tumours near the eyes, sinuses, brain or spinal cord
  • Multidisciplinary surgical approaches for tumours in the abdomen or pelvis
• Radiation Therapy
  • High-energy radiation delivered before surgery to shrink large tumours
  • Post-surgical radiation to destroy microscopic cancer cells left behind
  • Particularly recommended for high-risk tumours or incomplete surgical removal
  • Treatment typically delivered in daily fractions over several weeks
• Chemotherapy
  • Traditional chemotherapy drugs with limited effectiveness for most solitary fibrous tumours
  • May be considered for unresectable or metastatic disease
  • Better response rates observed in dedifferentiated solitary fibrous tumour subtype
• Targeted Therapy
  • Treatments available for tumours that cannot be removed by surgery or have spread
  • Used in cases where standard treatments are not suitable options

Promising Treatments in Clinical Trials

Antiangiogenic Therapy: Cutting Off the Tumour’s Blood Supply

One of the most promising developments in treating solitary fibrous tumours involves a class of drugs called antiangiogenic agents. These medications work by blocking the formation of new blood vessels, a process called angiogenesis. Like all tumours, solitary fibrous tumours need a blood supply to grow and survive. They accomplish this by sending out chemical signals that cause new blood vessels to sprout and connect to the tumour, bringing oxygen and nutrients. Antiangiogenic drugs interfere with these signals, essentially starving the tumour by cutting off its blood supply.^[11]

Clinical trials have shown that antiangiogenic compounds demonstrate higher effectiveness than traditional chemotherapy for most solitary fibrous tumours, based on indirect comparisons of different studies. This represents an important shift in how doctors approach treatment for tumours that cannot be completely removed by surgery or have already spread. What makes this approach even more interesting is that researchers have found that rotating between different antiangiogenic drugs when one stops working can continue to provide benefit to patients.^[5]

These trials typically involve patients whose tumours have progressed despite previous treatments or whose tumours are located in positions that make surgery impossible. The studies measure how long patients’ tumours remain stable without growing, how much tumours shrink, and how these treatments affect patients’ quality of life. While antiangiogenic therapy represents a significant advance, it’s important to note that it works differently than a cure—instead of eliminating the tumour, it often keeps it under control for extended periods.^[11]

Understanding NAB2-STAT6 Fusion: The Molecular Foundation

A major breakthrough in understanding solitary fibrous tumours came in 2013 with the discovery of abnormal fusion genes between NAB2 and STAT6. In normal cells, these two genes exist separately on chromosome 12, each performing their own functions. However, in solitary fibrous tumour cells, pieces of these genes break off and join together in the wrong way, creating a hybrid NAB2-STAT6 fusion gene. This genetic accident appears to be the driving force behind the development of solitary fibrous tumours.^[5]

This discovery has been transformative for several reasons. First, it provides a highly specific diagnostic marker—testing for the presence of STAT6 protein in cell nuclei has become a standard way to confirm the diagnosis of solitary fibrous tumour and distinguish it from other similar-looking tumours. Second, understanding this molecular driver has opened new avenues for developing targeted therapies. Researchers are now investigating drugs that might specifically interfere with the abnormal proteins produced by this fusion gene or the pathways they activate.^[5]

Different variations of the NAB2-STAT6 fusion exist, and scientists are studying whether certain variations are associated with more aggressive tumour behaviour. This knowledge could eventually allow doctors to predict more accurately how an individual patient’s tumour will behave and tailor treatment accordingly. Clinical trials are exploring whether drugs that target the pathways activated by this fusion gene can effectively treat solitary fibrous tumours, particularly those that have not responded to other therapies.^[5]

Phases of Clinical Trials and What They Mean

When researchers develop new treatments for solitary fibrous tumours, they must test them through a carefully regulated process involving different phases of clinical trials. Phase I trials are the first tests in humans, typically involving small numbers of patients. The primary goal is to determine what dose can be given safely and what side effects occur. These trials help researchers understand how the human body processes the drug and find the right balance between effectiveness and safety.^[3]

Phase II trials involve more patients and focus on determining whether the treatment actually works against the disease. Researchers carefully measure whether tumours shrink, stop growing, or at least grow more slowly. They also continue to monitor side effects and gather information about which patients seem to benefit most. For rare diseases like solitary fibrous tumour, Phase II trials are particularly important because they provide the first real evidence of whether a new approach is worth pursuing further.^[3]

Phase III trials are large studies that compare the new treatment directly against the current standard treatment. These trials aim to determine whether the new therapy is better than, equal to, or worse than existing options. They involve hundreds or even thousands of patients and provide the strongest evidence for whether a new treatment should become part of standard care. For solitary fibrous tumours, reaching Phase III trials has been challenging because the disease is so rare, making it difficult to enroll enough patients.^[3]

Geographic Availability of Clinical Trials

Clinical trials for solitary fibrous tumours are conducted in various locations around the world, though the rarity of the disease means that trial sites are often concentrated in major cancer centres with expertise in sarcomas. Trials have been conducted in the United States, throughout Europe including specialist sarcoma centres in countries like Spain, France, and the United Kingdom, and in other regions with advanced medical research infrastructure. Patients interested in clinical trials should work with their healthcare team to identify trials they might be eligible for, understanding that participation may require travelling to specialised centres.^[5]

Patient eligibility for clinical trials depends on many factors beyond just having a diagnosis of solitary fibrous tumour. Researchers typically look at the specific characteristics of the tumour, including its location, size, whether it has spread, and its molecular features. They also consider what previous treatments the patient has received, their overall health status, and sometimes their age. Some trials specifically seek patients whose tumours have progressed despite standard treatments, while others may be open to patients who are newly diagnosed.^[3]